Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Iamarangerboy who wrote (9498)	6/13/2006 11:11:42 AM
From: Iamarangerboy	Respond to of 10280

same... but more info....http://biz.yahoo.com/bw/060613/20060613005335.html?.v=1 Sepracor Announces Presentation of LUNESTA(TM) Data at Associated Professional Sleep Societies Annual Meeting Tuesday June 13, 7:00 am ET MARLBOROUGH, Mass.--(BUSINESS WIRE)--June 13, 2006--Sepracor Inc. (Nasdaq: SEPR - News) today announced that data for LUNESTA(TM) brand eszopiclone for the treatment of insomnia will be presented at the SLEEP 2006 20th Anniversary Meeting of the Associated Professional Sleep Societies at the Salt Palace Convention Center in Salt Lake City on June 20th and 22nd. There will be four oral presentations and four posters presented. The following poster presentations will take place on June 20, 2006 and will be accessible from 1:15 to 2:45 p.m. MDT in Ballrooms A-D: * Two Double-Blind, Placebo-Controlled, 6-Month Trials of Eszopiclone for Insomnia: Pooled Analysis by Race/Ethnicity * Analysis of Individual Items of the Hamilton Depression Scale in a Study of Eszopiclone/Fluoxetine Co-Therapy * Eszopiclone Co-Administered with Fluoxetine for Insomnia Co-Existing with Major Depressive Disorder (MDD): Analysis by Severity of Insomnia * Evaluation of Patient Satisfaction: Regimen of Eszopiclone Sleep Satisfaction Trial (RESST) The following oral presentations will take place on June 22, 2006 in Ballroom FH during the "Insomnia: Medication Effects" session, which begins at 8:00 a.m. MDT: * Efficacy and Safety of Six Months of Nightly Eszopiclone in Patients with Primary Insomnia: A Second Long-Term Placebo-Controlled Study * The Relationship Between Eszopiclone's Effects on Sleep and Depression in Patients with New Onset Major Depressive Disorder (MDD) and Insomnia: Surrogate Marker Analysis * Eszopiclone Treatment During Menopausal Transition: Sleep Effects, Impact on Menopausal Symptoms and Mood * The Effect of Eszopiclone 3 mg Compared with Placebo in Patients with Rheumatoid Arthritis and Co-Existing Insomnia